Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection

Jin Yong Kim(Incheon Medical Center), Kim Ys(Seoul National University), Nahyun Jung(Celltrion (South Korea)), Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), Oana Săndulescu(Carol Davila University of Medicine and Pharmacy), Yeon Mi Lee(Celltrion (South Korea)), Da Bee Jeon(Celltrion (South Korea)), Seul Gi Lee(University of Virginia), Jang Hee Hong(Chungnam National University Hospital), Yeo Jin Lee(Celltrion (South Korea)), Sung Hyun Kim(Celltrion (South Korea)), Min Kyung Kim(Celltrion (South Korea)), Bum Soo Kim(Celltrion (South Korea)), Sang Joon Lee(Celltrion (South Korea)), Jeong Eun Park(Chungnam National University Hospital), Jae‐Hyeong Park(Chungnam National University Hospital), Jin Gyu Jung(Chungnam National University Hospital), Young Rock Jang(Incheon Medical Center)
Clinical Therapeutics
August 22, 2021
Cited by 47


Related Papers